| 1 |
Single-vector inducible lentiviral RNAi system for oncology target validation
Dmitri Wiederschain, W Nicolson Susan, Lin Chen et al. · Cell Cycle
Open access |
Feb 2009 |
469 |
| 2 |
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen et al. · Nature Medicine
Open access |
23 Feb 2023 |
241 |
| 3 |
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
Pamela A. Trail, Gene M. Dubowchik, Timothy B. Lowinger · Pharmacology & Therapeutics
|
27 Jul 2017 |
137 |
| 4 |
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
Joan B. Mannick, Grace Sock Leng Teo, Bernardo Patti et al. · The Lancet Healthy Longevity
Open access |
May 2021 |
122 |
| 5 |
A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak et al. · Cancer Research
|
26 Jun 2015 |
105 |
| 6 |
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
Alexander V. Yurkovetskiy, Robert J. Fram · Advanced Drug Delivery Reviews
Review |
13 Aug 2009 |
99 |
| 7 |
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Naniye Malli Cetinbas, Travis E. Monnell, Jahna Soomer-James et al. · Nature Communications
Open access |
11 Jul 2024 |
87 |
| 8 |
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoît You, Christopher H. Purdy, Larry J. Copeland et al. · Journal of Clinical Oncology
Open access |
17 Oct 2022 |
81 |
| 9 |
Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Aleksandr V. Yurkovetskiy et al. · Molecular Cancer Therapeutics
|
15 Mar 2021 |
77 |
| 10 |
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry
Open access |
24 Jul 2023 |
56 |
| 11 |
The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Natalya D. Bodyak et al. · Molecular Cancer Therapeutics
|
15 Mar 2021 |
49 |
| 12 |
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Raghida A. Bukhalid et al. · Clinical Cancer Research
Open access |
3 Mar 2025 |
44 |
| 13 |
Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking
Xingfeng Bao et al. · Cancer Biology & Therapy
Open access |
2 Mar 2015 |
43 |
| 14 |
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Dorin Toader et al. · Molecular Cancer Therapeutics
Open access |
9 Jun 2023 |
41 |
| 15 |
2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies
Surinder Kaur et al. · Bioanalysis
Open access |
May 2022 |
31 |
| 16 |
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Armin Ghobadi et al. · Blood
Open access |
30 May 2025 |
30 |
| 17 |
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
Charles N. Landen, Ronald J. Buckanovich, Michael W. Sill et al. · Journal of Clinical Oncology
|
22 May 2024 |
26 |
| 18 |
Neuropilin-1 drives tumor-specific uptake of chlorotoxin
Sharon McGonigle, Utpal Majumder, Donna Kolber‐Simonds et al. · Cell Communication and Signaling
Open access |
17 Jun 2019 |
21 |
| 19 |
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
Armin Ghobadi et al. · Research Square
PreprintOpen access |
5 Aug 2024 |
19 |
| 20 |
A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS
Ling Xu, Laura E. Packer, Chao Li et al. · Analytical Biochemistry
|
Sep 2017 |
19 |
| 21 |
An Integrated Analysis of Dostarlimab Immunogenicity
Sharon M. Lu, Ronald R. Bowsher, Amanda Clancy et al. · The AAPS Journal
Open access |
29 Jul 2021 |
18 |
| 22 |
Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)
Debra L. Richardson, Erika Paige Hamilton, Minal A. Barve et al. · Gynecologic Oncology
|
Aug 2022 |
17 |
| 23 |
Delivering More Payload (High DAR ADCs)
Natalya D. Bodyak, Alexander V. Yurkovetskiy · Cancer drug discovery and develogment/Cancer drug discovery and development
Book chapter |
2018 |
16 |
| 24 |
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Mehmet Akce, Anthony B. El-Khoueiry, Sarina Anne Piha-Paul et al. · Cancer Chemotherapy and Pharmacology
Open access |
29 Jul 2021 |
15 |
| 25 |
836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Erika Paige Hamilton, Minal A. Barve, Anthony W. Tolcher et al. · Annals of Oncology
Open access |
Sep 2020 |
14 |
| 26 |
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Dana Meredith Chase, Jessica A. Perhanidis, Divya Myadam Gupta et al. · Oncology and Therapy
Open access |
4 Apr 2023 |
13 |
| 27 |
Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry
Ling Xu, Zhiling Zhang, Shengsheng Xu et al. · Journal of Pharmaceutical and Biomedical Analysis
|
11 Jun 2019 |
13 |
| 28 |
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Susan M. Clardy et al. · Molecular Cancer Therapeutics
|
29 Sep 2023 |
10 |
| 29 |
Determining the Stoichiometry of a Protein–Polymer Conjugate Using Multisignal Sedimentation Velocity Analytical Ultracentrifugation
Susan M. Clardy, David H. Lee, Peter Schuck · Bioconjugate Chemistry
|
13 Apr 2021 |
10 |
| 30 |
Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
Dana Meredith Chase, Jessica A. Perhanidis, Divya Gupta et al. · JCO Clinical Cancer Informatics
Open access |
Jun 2023 |
9 |
| 31 |
NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort
Sarah Heynemann, Hui Yu, Leonid P. Churilov et al. · Clinical Lung Cancer
|
16 Nov 2021 |
8 |
| 32 |
UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer
Debra J. Richardson et al. · Gynecologic Oncology
|
9 Oct 2024 |
7 |
| 33 |
Microglial roles in Alzheimer's disease: An agent‐based model to elucidate microglial spatiotemporal response to beta‐amyloid
Catherine Weathered, Sophia Bardehle, Choya Yoon et al. · CPT Pharmacometrics & Systems Pharmacology
Open access |
11 Dec 2023 |
7 |
| 34 |
Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates
Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Mao Yin et al. · Bioorganic & Medicinal Chemistry Letters
|
3 Jul 2022 |
6 |
| 35 |
Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)
Patrick R. Conlon, Venu R. Gurijala, Michael D. Kaufman et al. · Organic Process Research & Development
|
15 Feb 2022 |
6 |
| 36 |
MER-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model
Alex Yurkovetskiy, Mikhail I. Papisov, Alan J. Fischman et al. · Cancer Research
|
May 2007 |
6 |
| 37 |
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Stefanie R. Bailey, Eric Bartee, Kyle G. Daniels et al. · Journal for ImmunoTherapy of Cancer
Open access |
Aug 2025 |
5 |
| 38 |
298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC
E.P. Hamilton, Hee-Dong Han, Nour K. Abuhadra et al. · ESMO Open
Open access |
May 2025 |
5 |
| 39 |
184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer
Nicole Concin, Erika Paige Hamilton, LM Randall et al. · Ovarian cancer
Conference paperOpen access |
Oct 2021 |
5 |
| 40 |
Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer
Angela K. Green, Deborah R. Korenstein, Carol A Aghajanian et al. · Journal of the National Comprehensive Cancer Network
Open access |
Apr 2020 |
5 |
| 41 |
Antibody–Drug Conjugates
Dorin Toader · Topics in medicinal chemistry
Book chapter |
2017 |
5 |
| 42 |
Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies
Kevin S. McDorman, Bindu M. Bennet, Karyn A. Colman et al. · Toxicologic Pathology
|
Feb 2024 |
4 |
| 43 |
A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
Debra L. Richardson, E. Hamilton, A. W. Tolcher et al. · Gynecologic Oncology
|
Oct 2020 |
4 |
| 44 |
P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
Hui Yu, Rebecca E. Mosher, Kimberly S. Ellison et al. · Journal of Thoracic Oncology
Open access |
Oct 2018 |
4 |
| 45 |
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide
Niyanta N. Kumar, Vaishali S. Dixit, Howard J. Burt et al. · CPT Pharmacometrics & Systems Pharmacology
Open access |
31 Jul 2025 |
3 |
| 46 |
3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets
Susana N. Banerjee, Debra L. Richardson, Nicole Concin et al. · ESMO Open
Open access |
Feb 2023 |
3 |
| 47 |
620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates
Naniye Mallı Cetinbas, Travis E. Monnell, Winnie Lee et al. · Regular and Young Investigator Award Abstracts
Conference paperOpen access |
Nov 2020 |
3 |
| 48 |
#168 UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)
Nicole Concin et al. · International Journal of Gynecological Cancer
Open access |
Mar 2024 |
2 |
| 49 |
Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Mao Yin et al. · Molecular Cancer Therapeutics
|
13 Feb 2024 |
2 |
| 50 |
33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer
Debra J. Richardson, Jill H. Tseng, Theresa Louise Werner et al. · Gynecologic Oncology Reports
Open access |
Dec 2022 |
2 |